News Image

PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update

Provided By GlobeNewswire

Last update: Mar 27, 2025

Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer

Conference call and webcast today at 8:00 a.m. Eastern Time

Read more at globenewswire.com

PDS BIOTECHNOLOGY CORP

NASDAQ:PDSB (12/12/2025, 8:00:00 PM)

After market: 0.98 +0.01 (+0.61%)

0.9741

-0.04 (-3.55%)



Find more stocks in the Stock Screener

Follow ChartMill for more